Ann Hsu

Summary

Publications

  1. pmc Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients
    Ann Hsu
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Antimicrob Agents Chemother 47:350-9. 2003
  2. ncbi request reprint Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine
    Dale J Kempf
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois, USA
    J Infect Dis 189:51-60. 2004
  3. pmc Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir
    Dean Hickman
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Antimicrob Agents Chemother 48:2911-7. 2004
  4. pmc In vitro antiviral interaction of lopinavir with other protease inhibitors
    Akhteruzzaman Molla
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Antimicrob Agents Chemother 46:2249-53. 2002
  5. ncbi request reprint Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients
    Constance A Benson
    Department of Medicine, University of Colorado Health Sciences Center, 4200 E 9th Avenue, B 168, Denver, CO 80262, USA
    J Infect Dis 185:599-607. 2002
  6. pmc Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia
    Nancy Shulman
    Stanford University School of Medicine, California, USA
    Antimicrob Agents Chemother 46:3907-16. 2002
  7. ncbi request reprint The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease
    Soo Peang Khor
    Clinical Pharmacokinetics and Pharmacodynamics, IMPAX Laboratories, Inc Hayward, CA, USA
    Curr Clin Pharmacol 2:234-43. 2007

Collaborators

Detail Information

Publications7

  1. pmc Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients
    Ann Hsu
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Antimicrob Agents Chemother 47:350-9. 2003
    ..Multiple stepwise logistic regressions confirmed the significance of the IQ parameters, as well as other baseline characteristics, in predicting virologic response at 24 weeks in this patient population...
  2. ncbi request reprint Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine
    Dale J Kempf
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois, USA
    J Infect Dis 189:51-60. 2004
    ..These differences suggest substantially different genetic and pharmacological barriers to resistance for these 2 protease inhibitors and may have implications for strategies for initiating antiretroviral therapy...
  3. pmc Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir
    Dean Hickman
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Antimicrob Agents Chemother 48:2911-7. 2004
    ..Using this approach, we calculated the average IQs for protease inhibitor-naïve patients for LPV and RTV to be 67 and 5.6, respectively...
  4. pmc In vitro antiviral interaction of lopinavir with other protease inhibitors
    Akhteruzzaman Molla
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Antimicrob Agents Chemother 46:2249-53. 2002
    ..More importantly, the observed in vitro synergy between lopinavir and saquinavir provides a theoretical basis for the clinical exploration of a novel regimen of lopinavir-ritonavir and saquinavir...
  5. ncbi request reprint Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients
    Constance A Benson
    Department of Medicine, University of Colorado Health Sciences Center, 4200 E 9th Avenue, B 168, Denver, CO 80262, USA
    J Infect Dis 185:599-607. 2002
    ..Mean CD4 cell counts increased by 125 cells/muL. Three patients discontinued therapy for drug-related adverse events...
  6. pmc Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia
    Nancy Shulman
    Stanford University School of Medicine, California, USA
    Antimicrob Agents Chemother 46:3907-16. 2002
    ..The virtual inhibitory quotient, which incorporates both baseline viral resistance and the level of drug exposure in plasma, was superior to either baseline resistance or drug exposure alone in predicting the virologic response...
  7. ncbi request reprint The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease
    Soo Peang Khor
    Clinical Pharmacokinetics and Pharmacodynamics, IMPAX Laboratories, Inc Hayward, CA, USA
    Curr Clin Pharmacol 2:234-43. 2007
    ..The pharmacokinetics and pharmacodynamics data of levodopa reported in the literature are reviewed here...